Medical technology company Boston Scientific Corporation (NYSE: BSX) announced on Monday that it has entered into a definitive agreement to acquire Valencia Technologies Corporation, a privately held medical technology company focused on therapies for bladder dysfunction, strengthening its urology offering for patients with overactive bladder.

The transaction centres on Valencia's eCoin System, an implantable tibial nerve stimulation device for the treatment of urge urinary incontinence, a key symptom of overactive bladder. The device received approval from the United States Food and Drug Administration in 2022 and is implanted via a minimally invasive procedure near the ankle, delivering automated, intermittent stimulation to regulate bladder control. In the pivotal clinical trial, 68% of patients achieved at least a 50% reduction in urge urinary incontinence episodes.

Overactive bladder affects close to 30 million adults aged 40 and over in the US, with low treatment penetration beyond lifestyle interventions, highlighting a significant unmet clinical need. eCoin is intended for patients who have responded to percutaneous tibial nerve stimulation trials or who are intolerant of, or inadequately served by, conservative treatment options.

Completion of the acquisition is expected in the first half of 2026, subject to customary closing conditions. Boston Scientific said the deal is expected to have an immaterial impact on adjusted earnings per share in 2026, with greater dilution on a GAAP basis due to acquisition-related charges and amortisation. Financial terms were not disclosed.